Swedish Orphan Biovitrum AB/Skr SOBI
08:00
10:05
12:15
14:20
16:25
1D1W1MYTD1Y5YMAX
About Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB is a biotechnology company primarily focused on developing and commercializing specialty pharmaceuticals for rare diseases. The company is active in therapeutics for hematology, immunology, and genetic and metabolic disorders. Swedish Orphan Biovitrum was founded in 2001 and is headquartered in Stockholm, Sweden. The company operates globally, reaching markets in Europe, North America, and other regions. A key aspect of its strategic positioning is its commitment to addressing unmet medical needs in rare diseases, which often provides a unique market niche. The company invests significantly in research and development to fuel growth and innovation in its therapeutic areas.
Ticker
Skr SOBI
Sector
Primary listing
XSTO
Employees
1,888
Headquarters
Stockholm, Sweden
Website
SOBI Metrics
BasicAdvanced
kr 129B
271.24
kr 1.37
0.18
-
Price and volume
Market cap
kr 129B
Beta
0.18
52-week high
kr 432.80
52-week low
kr 24.78
Average daily volume
494K
Financial strength
Current ratio
0.904
Quick ratio
0.585
Long term debt to equity
14.418
Total debt to equity
30.472
Interest coverage (TTM)
9.63%
Profitability
EBITDA (TTM)
11,488
Gross margin (TTM)
78.87%
Net profit margin (TTM)
1.69%
Operating margin (TTM)
28.34%
Effective tax rate (TTM)
-1,300.00%
Revenue per employee (TTM)
kr 14,960,000
Management effectiveness
Return on assets (TTM)
7.00%
Return on equity (TTM)
1.22%
Valuation
Price to earnings (TTM)
271.241
Price to revenue (TTM)
4.531
Price to book
3.42
Price to tangible book (TTM)
-11.34
Price to free cash flow (TTM)
23.64
Free cash flow yield (TTM)
4.23%
Free cash flow per share (TTM)
15.719
Growth
Revenue change (TTM)
8.50%
Earnings per share change (TTM)
-87.81%
3-year revenue growth (CAGR)
14.54%
10-year revenue growth (CAGR)
24.22%
3-year earnings per share growth (CAGR)
-46.28%
10-year earnings per share growth (CAGR)
19.03%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Swedish Orphan Biovitrum AB stock?
Swedish Orphan Biovitrum AB (SOBI) has a market cap of Skr129B as of March 14, 2026.
What is the P/E ratio for Swedish Orphan Biovitrum AB stock?
The price to earnings (P/E) ratio for Swedish Orphan Biovitrum AB (SOBI) stock is 271.24 as of March 14, 2026.
Does Swedish Orphan Biovitrum AB stock pay dividends?
No, Swedish Orphan Biovitrum AB (SOBI) stock does not pay dividends to its shareholders as of March 14, 2026.
When is the next Swedish Orphan Biovitrum AB dividend payment date?
Swedish Orphan Biovitrum AB (SOBI) stock does not pay dividends to its shareholders.
What is the beta indicator for Swedish Orphan Biovitrum AB?
Swedish Orphan Biovitrum AB (SOBI) has a beta rating of 0.18. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.